

Date and Time: 15th April 2011, 10 am to 4 pm

Minutes: Confirmed

Guideline Development Group Meeting 8 Acute Upper GI Bleeding Guideline

Place: Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ

Present

GDG

1. Kelvin Palmer (Chair)	KP
2. Mimi McCord	MM
3. Kenneth Halligan	KH
4. Carlos Gomez	CG
5. Mark Vaughan	MV
6. Mark Donnelly	MD
7. David Patch	DP
8. Joseph Varghese	JV
9. Simon McPherson	SM
10. Dan Greer	DG
11. Markus Hauser	MK
12. Ricky Forbes-Young	RF

NICE / NCGC

13. Bernard Higgins	BH
14. Stephen Atkinson	SA
15. Katharina Dworzynski	KD
16. Vicki Pollit	VP
17. Amy Kelsey	AK
18. Mark Perry	MP
19. David Wonderling	DW
20. Andrew Gyton	AG

Observers

21. Jaymeeni Solanki	JS
----------------------	----

Apologies

1. Sarah Dunsdon	SD
2. Richard Anderson	RA

Notes

1. Introduction

The Chair welcomed attendees to the Acute Upper GI Bleeding (UGIB) guideline development group (GDG) meeting 8 and asked all GDG members to declare any relevant conflicts of interest. All members declare that they had no personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role).

Then the meeting notes, minutes, and LETR of the last meeting of this group were agreed as a true and accurate account of the meeting.

Subsequently, the Chair briefed the group on the objectives of the GDG meeting 8.

2. Reviewing of clinical and health economic evidence to address the following key clinical question:

- i. **In patients presenting with UGIB who are already on NSAIDs, Clopidogrel, Aspirin or dipyridamol (single or combination) what is the evidence that discontinuation compared to continuation of the medication leads to better outcome?**

Clinical and Economic evidence was presented for the GDG's consideration. The evidence was discussed and a draft recommendation was developed.

- ii. **For acutely ill patients in high dependency and intensive care units are Proton Pump Inhibitors (PPIs) or H2-receptor antagonists better than placebo in the primary prophylaxis of Upper Gastrointestinal Bleeding (UGIB)?**

Clinical and Economic evidence was presented for the GDG's consideration. The evidence was discussed and a draft recommendation was developed.

3. Update on HE Analysis on "Timing of Endoscopy"

VP presented progress on the development of the in-house health-economic (HE) model that assesses the cost-effectiveness of the "timing of endoscopy". The GDG discussed the inputs into the model and agreed next steps.

4. Building the guideline – Chapter Introductions

The Chair updated the group on the progress of the guideline build, specifically the chapter introductions.

5. AOB

There was no AOB.

Date, time and venue of the next meeting

The next GDG meeting will take place on the 27th May, 2011 from 10 am to 4 pm, at the National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ

